Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

3 Stocks Making Health-Care Investors Big Money Today

By Dave Williamson - Mar 10, 2014 at 6:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The three biggest winners in health care today, and what drove the pops that are making investors big money.

Despite an overall down day on the market today, the health-care sector emerged looking pretty good, with a handful of big winners. In this video, Motley Fool health-care analyst David Williamson looks at three top performers.

Regado Biosciences (NASDAQ: RGDO) is the day's biggest winner, up 33% after announcing a fast-track designation for its lead drug candidate REG1, a new type of anticoagulant therapy that would be used during percutaneous coronary intervention procedures. The drug is just beginning late stage development with enrollment ongoing in its phase 3 trial. The stock has gone on a big run over the last month as the FDA accepted an investigational new drug, or IND, application for its next drug REG2. David sees this as definitely an exciting biotech to keep an eye on this year.

Northwest Biotherapeutics ( NWBO 1.27% ) is today's next winner, up 29% today after some good news coming out of Europe for the company's brain cancer vaccine DCVax-L. German hospitals are allowed to give the drug to patients with any type of glioma brain cancer, whether they are newly diagnosed or recurrent, under the compassionate use standard. Shares are soaring because the company can charge full price for these treatments outside of its ongoing phase 3 clinical studies. David, however, advises caution here, saying that he doesn't see this adding any meaningful sales. With the big tear the stock has been on, any bad news coming out of these phase 3 trials could be crushing for investors.

And finally, Alexion ( ALXN ) is today's third winner, up 7% on great guidance for sales of its drug Soliris. The company was able to add an additional $150 million in 2014 sales up to $2.15 billion, thanks to an agreement with the French. As this is one of the most expensive drugs in the world at $400k, negotiation with each European country for reimbursement is critical to expansion. David still sees a significant upside in global sales for the drug as well as the potential here for additional indications, and says that Alexion is the one he sees as the safest investment of today's three winners for biotech growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN
Northwest Biotherapeutics, Inc. Stock Quote
Northwest Biotherapeutics, Inc.
NWBO
$0.80 (1.27%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.